Skip to main content
Advertising

Originally published December 3, 2013 at 5:03 AM | Page modified December 4, 2013 at 6:28 AM

  • Share:
           
  • Comments (0)
  • Print

Blaze Bioscience raises $9M

Blaze Bioscience has raised $9 million to further its clinical development of its first product designed to illuminate cancer cells during surgery.


By Seattle Times business staff

Most Popular Comments
Hide / Show comments
No comments have been posted to this article.
Start the conversation >

advertising

Blaze Bioscience has raised $9 million to further its development of its first product designed to illuminate cancer cells during surgery.

The financing, mostly from previous investors, brings the Seattle biotechnology company’s total funding since 2010 to $19 million.

The company says its product candidate BLZ-100, the first using a technology it calls Tumor Paint, can assist surgeons in removing solid tumors by making cancer cells visible with a fluorescent dye.



News where, when and how you want it

Email Icon

Seattle Sketcher Book

Seattle Sketcher Book

Take home the Seattle Sketcher's latest book! Available now.

Advertising

Advertising


Advertising
The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►